Skip to content

US · GNPX · BIOTECHNOLOGY

Genprex, Inc. (GNPX) intrinsic value and stock valuation

$1.45as of 2026-11-21 · Mkt cap 2.16M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Genprex, Inc. DCF and intrinsic value

InvestorsCraft values GNPX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from GNPX’s statements →

Genprex, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Austin, TX 78746 genprex.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$0.00
20152025
Net income
-$-16.23M
20152025
Free cash flow
-$-15.31M
20152025
Total equity
$7.96M-23.8% 5y CAGRd
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-15.52M-$-21.17M-$-31.08M-$-23.83M-$-20.67M
Net income-$-16.23M-$-21.11M-$-30.86M-$-23.74M-$-20.66M
EPSd-$-405.75M————
Operating cash flow-$-15.31M-$-17.15M-$-24.74M-$-17.78M-$-14.28M
Capital expenditure-$0.00$0.00-$-70K$0.00-$-80K
Free cash flow-$-15.31M-$-17.15M-$-24.81M-$-17.78M-$-14.37M
Total assets$10.2M$4.12M$10.7M$25.1M$42.9M
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-7.83M-$-1.6M-$-6.74M-$-20.95M-$-38.63M
Total equity$7.96M$1.62M$7.42M$22.3M$41.3M
Cash and short-term investments$7.83M$1.6M$6.74M$21M$38.6M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$10K$20K$30K$20K
Gross profit$0.00-$-10K-$-20K-$-30K-$-20K
Research and development expenses$9.43M$10.5M$17.6M$11.5M$8.97M
Selling, general and administrative expenses$6.09M$10.6M$13.4M$12.3M$11.7M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$15.5M$21.2M$31.1M$23.8M$20.7M
Cost and expenses$15.5M$21.2M$31.1M$23.8M$20.7M
Interest income$0.00$60K$220K$90K$10K
Interest expense$740K$0.00$0.00$0.00$0.00
Depreciation and amortization$0.00$10K$20K$30K$20K
Ebitda-$-15.49M-$-21.1M-$-30.85M-$-23.72M-$-20.64M
Operating income-$-15.52M-$-21.17M-$-31.08M-$-23.83M-$-20.67M
Total other income/expenses, net-$-710K$60K$220K$90K$10K
Income before tax-$-16.23M-$-21.11M-$-30.86M-$-23.74M-$-20.66M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-16.23M-$-21.11M-$-30.86M-$-23.74M-$-20.66M
Weighted average shares outstanding$40K$0.00$0.00$0.00$0.00
Weighted average diluted shares outstanding$40K$0.00$0.00$0.00$0.00
Balance sheet
20252024202320222021
Cash and short-term investments$7.83M$1.6M$6.74M$21M$38.6M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$8.36M$2.08M$7.53M$21.5M$39.1M
Property, plant and equipment, net$0.00$0.00$10K$20K$50K
Goodwill and intangible assets$0.00$0.00$770K$700K$640K
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.8M$2.05M$3.14M$3.61M$3.72M
Total assets$10.2M$4.12M$10.7M$25.1M$42.9M
Accounts payable$740K$1.07M$1.4M$440K$970K
Short-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$2.17M$2.5M$3.25M$2.81M$1.59M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$20K$0.00$0.00$0.00-$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$2.2M$2.5M$3.25M$2.81M$1.59M
Common stock$0.00$10K$0.00$0.00$50K
Retained earnings-$-171.03M-$-154.8M-$-133.69M-$-102.83M-$-79.09M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$7.96M$1.62M$7.42M$22.3M$41.3M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-7.83M-$-1.6M-$-6.74M-$-20.95M-$-38.63M
Cash flow statement
20252024202320222021
Net income-$-16.23M-$-21.11M-$-30.86M-$-23.74M-$-19.59M
Depreciation and amortization$0.00$10K$20K$30K$20K
Stock-based compensation$310K$3.3M$5.41M$4.73M$5.35M
Change in working capital-$-140K-$-120K$700K$1.2M$1.01M
Accounts receivable$0.00$0.00$30K-$-30K$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-330K-$-320K$950K-$-530K$780K
Net cash provided by operating activities-$-15.31M-$-17.15M-$-24.74M-$-17.78M-$-14.28M
Investments in property, plant and equipment$0.00$0.00-$-70K-$-60K-$-80K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00-$-70K$100K-$-80K
Common stock issued$21.5M$12M$10.6M$10K$25.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00-$-277.12M$0.00$0.00$0.00
Net cash used for financing activities$21.5M$12M$10.6M$10K$25.7M
Net change in cash$6.23M-$-5.14M-$-14.22M-$-17.67M$11.3M
Cash at end of period$7.83M$1.6M$6.74M$21M$38.6M
Operating cash flow-$-15.31M-$-17.15M-$-24.74M-$-17.78M-$-14.28M
Capital expenditure-$0.00$0.00-$-70K$0.00-$-80K
Free cash flow-$-15.31M-$-17.15M-$-24.81M-$-17.78M-$-14.37M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Genprex, Inc.

        Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.

        CEO
        Ryan Confer
        Employees
        13
        Beta
        -0.91

        Explore

        Frequently asked questions

        What is the intrinsic value of Genprex, Inc. (GNPX)?

        InvestorsCraft does not currently publish an intrinsic value for GNPX. How the IC value is calculated.

        Is GNPX undervalued?

        InvestorsCraft does not publish an undervaluation signal for GNPX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.